Morgan Stanley Call 116 6MK 19.12.../ DE000ME2EYK6 /
14/08/2024 13:21:37 | Chg.0.00 | Bid18:19:07 | Ask18:19:07 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.24EUR | 0.00% | 1.18 Bid Size: 50,000 |
1.19 Ask Size: 50,000 |
MERCK CO. D... | 116.00 - | 19/12/2025 | Call |
GlobeNewswire
25/06
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...